Skip to main content
Figure 2 | International Journal of Emergency Medicine

Figure 2

From: Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism

Figure 2

Kaplan-Meier curves for the principal efficacy and bleeding outcomes in the RE-COVER study. Incidences of (A) recurrent, symptomatic venous thromboembolism or related death and (B) major bleeding and any bleeding with dabigatran versus warfarin [20]. From The New England Journal of Medicine: Schulman et al., “Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism”, volume 361, pages 2342–2352. Copyright © 2009, Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

Back to article page

International Journal of Emergency Medicine

ISSN: 1865-1380

Contact us